Last kr546.50 DKK
Change Today +25.50 / 4.89%
Volume 428.2K
As of 11:06 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

genmab a/s (GEN) Snapshot

Open
kr530.00
Previous Close
kr521.00
Day High
kr552.50
Day Low
kr530.00
52 Week High
03/5/15 - kr552.50
52 Week Low
05/20/14 - kr180.10
Market Cap
31.1B
Average Volume 10 Days
301.6K
EPS TTM
kr5.43
Shares Outstanding
57.0M
EX-Date
--
P/E TM
100.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for GENMAB A/S (GEN)

Related News

No related news articles were found.

genmab a/s (GEN) Related Businessweek News

No Related Businessweek News Found

genmab a/s (GEN) Details

Genmab A/S, a biotechnology company, develops human antibody therapeutics for the treatment of cancer in Denmark, the Netherlands, the United States, and internationally. Its product pipeline includes Ofatumumab, a human monoclonal antibody, which is in Phase IV clinical studies for the treatment of chronic lymphocytic leukemia; Phase III clinical studies to treat follicular lymphoma, diffuse large B-cell lymphoma, and pemphigus vulgaris; Phase II clinical studies for the treatment of relapsing-remitting multiple sclerosis, and Waldenstrom’s Macroglobulinemia, as well as Daratumumab, a human CD38 monoclonal antibody that is in Phase I/II clinical studies to treat multiple myeloma. The company’s product pipeline also comprises HuMax-TF-ADC, an antibody-drug conjugate (ADC), which is in Phase I clinical studies for the treatment of solid tumors; and Teprotumumab, a human antibody that is in Phase II clinical studies for the treatment of active thyroid eye disease. In addition, it has approximately ten active pre-clinical pipeline programs, including naked antibodies and bispecific antibodies developed using DuoBody technology and ADC. The company has collaborations with GlaxoSmithKline, Janssen Biotech, Inc. (Janssen), Seattle Genetics, Inc., Roche, and H. Lundbeck A/S; and technology partnerships with Medarex, Novartis, and Janssen. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

Founded in 1999

genmab a/s (GEN) Top Compensated Officers

Co-Founder, Chief Executive Officer and Presi...
Total Annual Compensation: kr11.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr5.2M
Compensation as of Fiscal Year 2014.

genmab a/s (GEN) Key Developments

Genmab A/S Proposes Amendments to its Articles of Association

Genmab A/S announced that at its AGM to be held on March 26, 2015, the company has proposed to approve the amendments to its article of association regarding change of NASDAQ OMX Copenhagen A/S' trademark in Article 8 and change in the deadline for voting by post in Article 10 of the company's Articles of Association.

Genmab A/S Announces Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Genmab A/S announced audited consolidated and parent earnings results for the year ended December 31, 2014. For the year, on consolidated basis, the company reported revenue of DKK 850,385,000 against DKK 663,570,000 a year ago. Operating result was DKK 265,177,000 against DKK 69,253,000 a year ago. Net result for continuing operations before tax was DKK 297,346,000 against DKK 65,402,000 reported a year ago. Net result for continuing operations was DKK 301,296,000 or DKK 5.26 per diluted share against DKK 70,155,000 or DKK 1.35 per diluted share reported a year ago. Net result was DKK 301,296,000 or DKK 5.26 per diluted share against DKK 112,362,000 or DKK 2.16 per diluted share reported a year ago. Cash flow from operating activities was DKK 132,671,000 against cash flow used in operating activities of DKK 127,999,000 a year ago. Investment in intangible assets was DKK 63,259,000 against DKK 2,723,000 a year ago. Investment in tangible assets was DKK 12,183,000 against DKK 7,642,000 a year ago. For the year, on parent basis, the company reported revenue of DKK 853,024,000 against DKK 665,171,000 a year ago. Operating result was DKK 322,174,000 against DKK 86,582,000 a year ago. Net result for continuing operations before tax was DKK 355,396,000 against DKK 97,694,000 reported a year ago. Net result for continuing operations was DKK 361,521,000 against DKK 98,944,000 reported a year ago. Net result was DKK 361,521,000 against DKK 125,117,000 reported a year ago. Cash flow from operating activities was DKK 165,673,000 against cash flow used in operating activities of DKK 113,776,000 a year ago. Investment in tangible assets was DKK 322,000 against DKK 45,000 a year ago. Investment in intangible assets was DKK 63,259,000 against DKK 2,723,000 a year ago. The company provides earnings guidance for the year 2015. For the year, the company expects revenue to be in the range of DKK 650 million to DKK 725 million compared to DKK 850 million reported in 2014. The company expects operating income to be in the range of DKK 200 million to DKK 275 million compared to DKK 265 million reported in 2014.

Genmab A/S Enters Commercial Duobody Technology Agreement with BioNovion in the Field of Immuno-Oncology

Genmab A/S announced it has entered a co-development and commercialization agreement with BioNovion to evaluate a number of DuoBody product candidates targeting immune checkpoints. Genmab and BioNovion will contribute panels of antibodies for the creation of bispecific antibody products using Genmab's DuoBody platform technology. If the companies jointly select a product candidate for clinical development, development costs will be shared equally, with each party retaining a 50% share of the product rights. If one of the companies decides not to move a therapeutic candidate forward, the other company is entitled to continue developing the product at predefined licensing terms. The agreement also includes terms which allow the parties to opt out of joint development at key points in each product's clinical development. This commercial agreement follows a July 2014 research collaboration between Genmab and BioNovion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEN:DC kr546.50 DKK +25.50

GEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.75 EUR +0.201
Dyax Corp $15.48 USD -0.19
ImmunoGen Inc $7.91 USD +0.18
MorphoSys AG €74.35 EUR +0.90
Seattle Genetics Inc $35.80 USD +0.68
View Industry Companies
 

Industry Analysis

GEN

Industry Average

Valuation GEN Industry Range
Price/Earnings 91.0x
Price/Sales 32.0x
Price/Book 13.4x
Price/Cash Flow 90.5x
TEV/Sales 28.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENMAB A/S, please visit www.genmab.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.